Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

Essers, Brigitte; Seferina, Shanley C.; Tjan‐Heijnen, Vivianne C. G.; Severens, Johan L.; Novák, Annoesjka; Pompen, Marjolein; Oron, Ulrich H.; Joore, Manuela A.

doi:10.1111/j.1524-4733.2009.00683.x

Cited by 29 publications

(39 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty-nine percent of respondents indicated that there were no guidelines for conducting HTA in their countries, but 11% did not answer this question. Sixty-two percent said they used HTA reports that had been produced in other jurisdictions to help in their decisions, which agrees with findings from other authors (15)(16)(17)(18)(19)(20)(21). HTA work produced in different contexts is usually adapted to the local situation in order to be used in the decision-making process.…”

Section: Discussionsupporting

confidence: 77%

Strengthening and implementing health technology assessment and the decision-making process in the Region of the Americas

Lessa

Caccavo

Curtis

et al. 2017

Rev Panam Salud Publica

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 77%

Strengthening and implementing health technology assessment and the decision-making process in the Region of the Americas

Lessa

Caccavo

Curtis

et al. 2017

Rev Panam Salud Publica

View full text Add to dashboard Cite

show abstract

“…Transferability of evidence—especially backed up by an economic model—is often a debated issue, because transferring evidence requires context‐specific data to go into the model 23, but often such data are either not available or the collection of such data is severely constrained by limited resources 5. Not being able to transfer evidence because of the unavailability of context‐specific data has severe opportunity cost implications; if transferred, the evidence could have saved lives (health outcomes) as well as money (economic outcomes) in new countries 24.…”

Section: Discussionmentioning

confidence: 99%

A utility of model input uncertainty analysis in transferring tobacco control‐related economic evidence to countries with scarce resources: results from the EQUIPT study

Németh¹,

Kulchaitanaroaj

Lester‐George

et al. 2018

Addiction

View full text Add to dashboard Cite

AimsTo inform the transferability of tobacco control‐related economic evidence to resource‐poor countries.MethodsWe ran a univariate sensitivity analysis on a return on investment (ROI) model, the European study on Quantifying Utility of Investment in Protection from Tobacco model (EQUIPTMOD), to identify key input values to which the ROI estimates were sensitive. The EQUIPTMOD used a Markov‐based state transition model to estimate the ROI of several tobacco control interventions in five European countries (England, Germany, Spain, Hungary and the Netherlands). Base case ROI estimates were obtained through average values of model inputs (throughout the five countries), which were then replaced one at a time with country‐specific values. Tornado diagrams were used to evaluate the significance of sensitivity, defined as a ≥ 10% difference in ROI estimates from the base case estimates.ResultsThe ROI estimates were sensitive to 18 (of 46) input values. Examples of model inputs to which ROI estimates were sensitive included: smoking rate, costs of smoking‐related diseases (e.g. lung cancer) and general population attributes.ConclusionCountries that have limited research time and other resources can adapt EQUIPTMOD to their own settings by choosing to collect data on a small number of model inputs. EQUIPTMOD can therefore facilitate transfer of tobacco control related economic evidence to new jurisdictions.

show abstract

“…Different chemotherapy regimens were considered according to local guidelines and expert opinions. The overall cost of a metastatic relapse was extracted from a study in each country [19,33,34].…”

Section: Costsmentioning

confidence: 99%

European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer

Marguet

Mazouni

Ramaekers

et al. 2016

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands

Abstract: Transferability of a model-based UK-study in three steps proved to be an efficient method to provide an early indication of the cost-effectiveness of trastuzumab and has led to the provisional reimbursement of the treatment.

Cited by 29 publications

References 12 publications

Strengthening and implementing health technology assessment and the decision-making process in the Region of the Americas

Strengthening and implementing health technology assessment and the decision-making process in the Region of the Americas

A utility of model input uncertainty analysis in transferring tobacco control‐related economic evidence to countries with scarce resources: results from the EQUIPT study

European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer

Contact Info

Product

Resources

About